Kiniksa Pharmaceuticals International, plc
KNSA
Classifica tra le azioni
#2875
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company,... Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Prezzo delle azioni
$83.13
Ultima sincronizzazione: 2026-10-20
Capitalizzazione di mercato
$6.49B
Variazione (1 giorno)
4.59%
Variazione (1 anno)
113.97%
Paese
GB
Scambia Kiniksa Pharmaceuticals International, plc (KNSA)
Categoria
Healthcare
Ricavi di Kiniksa Pharmaceuticals International, plc (KNSA)
Ricavi nel Jun 2026 TTM: $840.85M
Secondo gli ultimi rapporti finanziari di Kiniksa Pharmaceuticals International, plc, i ricavi attuali dell'azienda (TTM) sono pari a $840.85M. Nel 2023, l'azienda ha registrato ricavi di $270.26M un aumento rispetto a i ricavi dell'anno 2022, che erano pari a $220.18M. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Kiniksa Pharmaceuticals International, plc da 2016 a 2026
Ricavi alla fine di ogni anno
| Anno | Ricavi | Cambia |
|---|---|---|
| 2026 (TTM) | $840.85M | 98.67% |
| 2024 | $423.24M | 56.60% |
| 2023 | $270.26M | 22.74% |
| 2022 | $220.18M | 471.24% |
| 2021 | $38.54M | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
Ricavi di aziende simili o concorrenti
| Azienda | Ricavi | Differenza nei ricavi | Il paese |
|---|---|---|---|
| $2.54B | 201.60% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $830.81M | -1.19% |
US
|
